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PEMENCILAN BERPANDU BIO-AKTIVITI AILANTHUS MALABARICA 
UNTUK AKTIVITI PERENCATAN TOXOPLASMA GONDII DAN 
KOLINESTERASE 
 
ABSTRAK 
 
 Tumbuh-tumbuhan daripada Ailanthus genus diedarkan secara meluas di 
seluruh Asia dan memainkan peranan penting sebagai tumbuhan perubatan. Aktiviti-
aktiviti biologi spesies Ailanthus telah dikaji secara meluas dan didapati mempunyai 
aktiviti seperti anti-protozoa, anti-virus, anti-bakteria dan anti-fungal. Kajian ini 
bertujuan untuk menilai perencatan aktiviti Toxoplasma gondii dan enzim 
kolinesterase, serta analisis fitokimia untuk ekstrak metanol Ailanthus malabarica. 
Dalam kajian ini, ekstrak metanol Ailanthus malabarica disiasat bagi aktiviti-aktiviti 
anti-parasit terhadap Toxoplasma gondii. IC50 daripada anti-parasit aktiviti Ailanthus 
malabarica adalah 11.12 μg/mL. Ailanthus malabarica diperingkatkan dengan 
mengguna kromatografi resin untuk menghasilkan lima fraksi. Fraksi yang paling 
aktif ialah AM F5 dengan IC50 9.98 μg/mL. Selepas itu, AM F5 diperingkatkan 
menggunai kromatografi silika gel untuk menghasilkan ocotillone. IC50 untuk 
ocotillone adalah 16.18 μg/mL. Ailanthus malabarica kemudian diuji pada sel Vero 
dalam keadaan in vitro dengan menggunakan MTS assay untuk mengaji tahap toksik. 
Ekstrak dan fraksi telah didapati tidak toksik kepada sel-sel (LC50> 20 μg / mL). 
AM F3, AM F4 dan ocotillone menunjukkan tahap toksik yang rendah pada nilai 
LC50 247 μg/mL, 238 μg/mL dan 223 μg/mL masing-masing. Tahap toksik AM F5 
adalah tinggi berbanding dengan fraksi lain dengan nilai 49.87 μg/mL. Indeks 
pemilihan (SI) daripada ocotillone menunjukkan pemilihan tertinggi iaitu 13.83. 
xii 
 
Disebabkan Toxoplasma gondii adalah parasit neurotropic, jangkitan telah dibukti 
akan menyebabkan perubahan tingkah laku dan gejala neurocognitive dalam 
mamalia. Dalam kajian berikutnya, Ailanthus malabarica telah diuji untuk 
perencatan enzim kolinesterase. Pemeringkatan berulang AM F5 menghasilkan 
sebatian lain, AM S4 (hydroxydammarenone-II). Ekstra dan fraksi telah diuji untuk 
perencatan kedua-dua acetylcholinesterase (AChE) dan butyrylcholinesterase 
(BuChE). Pada 100 μg/mL, AM S4 (hydroxydammarenone-II), AM S6 dan AM S8 
daripada AM F5 menunjukkan perencatan melebihi 50 %. IC50 daripada ketiga-tiga 
pecahan ini adalah 12.54 μg/mL, 10.00 μg/mL dan 76.05 μg/mL masing-masing. 
Sebaliknya, untuk perencatan BuChE aktiviti, AM S10 dan AM S14 menunjukkan 
perencatan yang melebihi 50% apabila diuji di kepekatan 100 μg/mL. IC50 AM S10 
dan AM S14 pada BuChE adalah 2.98 μg/mL dan 25.31 μg/mL masing-masing. 
AM F5 yang memiliki kesan anti- toxoplasmicidal tertinggi dinilai kepada aktiviti 
anti- cholinesterase . Tetapi, perencatan enzim kolinesterase AM F5 adalah kira-kira 
13 %. Ocotillone yang didapati merencat pertumbuhan Toxoplasma gondii 
menunjukkan perencatan di acetylcholinesterase pada 34 % dan 18 % pada 
butyrylcholinesterase . Peratusan perencatan adalah agak rendah berbanding dengan 
lain-lain pecahan. Struktur AM S4 dan AM S7 telah ditentukan sebagai 
hydroxydammarenone-II dan ocotillone masing-masing dengan menggunakan NMR , 
IR dan spektroskopi jisim. Sebagai kesimpulan, hanya AM S4 
(hydroxydammarenone -II) menunjukkan aktiviti anti-acetylcholinesterase yang aktif 
pada 12 μg/mL. Bagaimanapun , sub-fraksi ini perlu diuji ke atas aktiviti anti-
toxoplasma untuk menentukan kesan terhadap Toxoplasma gondii. 
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BIOACTIVITY-GUIDED ISOLATION OF AILANTHUS MALABARICA FOR 
TOXOPLASMA GONDII AND CHOLINESTERASE INHIBITORY 
ACTIVITY 
 
ABSTRACT 
 
 The plants of the genus Ailanthus are distributed widely over Asia and play a 
significant role as medicinal plant. Biological activities of Ailanthus species has been 
studied extensively and found to possess activities like anti-protozoal, anti-viral, anti-
bacterial and anti-fungal. The present study aimed to evaluate the anti-toxoplasma 
and cholinesterase inhibitory activity, as well as phytochemical analysis of 
methanolic extract of Ailanthus malabarica. In this work, the methanolic extract of 
Ailanthus malabarica was investigated for the anti-parasitic activities against 
Toxoplasma gondii. The IC50 of Ailanthus malabarica on the anti-parasitic activity 
was 11.12 µg/mL. Ailanthus malabarica was further fractionated using resin column 
chromatography to yield five fractions. The most active fraction was AM F5 with 
IC50 of 9.98 µg/mL. AM F5 was then further subjected to silica gel column 
chromatography to yield ocotillone. The IC50 of ocotillone was 16.18 µg/mL. 
Ailanthus malabarica was then tested on Vero cell line in an in vitro MTS assay to 
study for the cytotoxicity of the plant. The crude extract as well as the sub-fractions 
were not toxic to the cells (TD50 > 20 µg/mL). AM F3, AM F4 and ocotillone 
showed little cytotoxicity at TD50 value of 247 µg/mL, 238 μg/mL and 223 μg/mL 
respectively. AM F5 was the most toxic at TD50 of 49.87 µg/mL. The selectivity 
index (SI) of ocotillone showing the highest selectivity was 13.83. As Toxoplasma 
gondii was a neurotropic parasite, the infection has been shown to cause behavioral 
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changes and neurocognitive symptoms in mamalian hosts. In subsequent study, 
Ailanthus malabarica was tested for cholinesterase enzyme inhibition. Fraction AM 
F5 which was found active in anti-toxoplasmic activity was subjected to anti-
cholinesterase inhibitory assay. Repeated fractionation of AM F5 yielded another 
compound, AM S4 (hydroxydammarenone-II). The crude extract and the sub-
fractions were tested for inhibition of both acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE). At 100 µg/mL, AM S4 (hydroxydammarenone-II), 
AM S6 and AM S8 from AM F5 showed above 50 % of inhibition on AChE. The 
IC50 of these three sub-fractions were 12.54 µg/mL, 10.00 µg/mL and 76.05 µg/mL 
respectively. On the other hand, for inhibition of BuChE, AM S10 and AM S14 
showed inhibition above 50 % when tested at the concentration of 100 µg/mL. The 
IC50 of AM S10 and AM S14 on BuChE were 2.98 µg/mL and 25.31 µg/mL 
respectively. AM F5 which possessed highest anti-toxoplasmicidal effect was 
evaluated on the anti-cholinesterase activity. However, the inhibition on 
cholinesterase enzymes of AM F5 was about 13 %. Ocotillone which was found to 
inhibit the growth of Toxoplasma gondii showed inhibition at acetylcholinesterase at 
34 % and 18 % on butyrylcholinesterase. The percentage of inhibition was 
comparatively lower when compared to other sub-fractions. AM S4 and AM S7 were 
structurally elucidated as hydroxydammarenone-II and ocotillone respectively by 
using NMR, IR and mass spectrometer. Only AM S4 (hydroxydammarenone-II) 
showed potent anti-acetylcholinesterase activity at 12 µg/mL. However, this sub-
fraction was not tested on anti-toxoplasmicidal activity due to laboratory limitations. 
In conclusion, AM F5 is potent against anti-toxoplasmic and cholinesterase 
inhibitory activity, however further study should be evaluated on the potency of 
hydroxydamarenone-II on anti-toxoplasmic activity to further confirm that it is the 
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compound which is responsible to inhibit both toxoplasma and cholinesterase 
activities.
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Toxoplasmosis: Overview 
Toxoplasmosis is a disease caused by an obligate intracellular parasite, Toxoplasma 
gondii. The discovery of Toxoplasma gondii can be dated back to 100 years ago, by 
scientists in North Africa and in Brazil. Toxoplasma gondii is capable of infecting all 
warm-blooded animals including humans. This protozoan parasite infects up to a 
third of the world's population and mainly through consumption of undercooked food 
containing tissue cysts or by ingestion of food and water that is contaminated with 
oocysts shed by cats (Bowie et al., 1997). Most of the infections of Toxoplasma in 
humans are asymptomatic, however, there are times where the infections lead to 
devastating disease. Encephalitis causes severe damage, making it the most 
important manifestation of toxoplasmosis in immune suppressed patients. The 
infection may be found in any organs, causing symptom-like headache, 
disorientation and drowsiness. Apart from that, toxoplasmosis can be acquired 
congenitally and post-natally. Sero-negative pregnant women may be at risk of 
contracting Toxoplasma gondii infection. This congenital infection may cause the 
fetuses to be infected and develop severe complications and sometimes causing death. 
The prevalence varied from place to place where it is estimated that 16-40 % of the 
population was infected in the United States and the United Kingdom (Hill & Dubey, 
2002). In Malaysia, the epidemiological surveys indicate that Toxoplasma antibody 
is found in all ethnic groups with Malays having the highest percentage at 33 %, 
followed by Indians at 29 % and Chinese at 18 % (Tee et al., 1998).  
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1.1.1 Apicomplexan parasites  
Parasites refer to organisms that depend on the hosts to survive and at the same time 
causing diseases to the hosts. These pathogenic parasites can be harmful to human as 
well as some economically important animal species. One of the most important 
groups of parasites is the apicomplexan parasites (Table 1) that include Plasmodium 
spp., the causative agent of malaria, Cryptosporidium, an opportunistic intestinal 
pathogen and also Toxoplasma gondii. Infection by protozoan parasites of the 
phylum Apicomplexa sometimes leads to mortality of human and livestock. 
 
Table 2.1 Taxonomic classification of Toxoplasma gondii 
 
There are some morphological traits that are shared among the parasites in the 
phylum apicomplexa. These protists are elongated in shape and have a specialised 
apical region. The apical complex consists of a collection of unique organelles with 
unique functions (Morrissette & Sibley, 2002). Apart from the apical complex, a 
highly conserved DNA of 35 kb has been discovered from several genera within the 
Taxonomic Classification 
Kingdom Chromalveolata 
Phylum Apicomplexa 
Class Conoidasida 
Order Eucoccidiorida 
Family Sarcosystidae 
Genus Toxoplasma 
Species gondii 
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phylum Apicomplexa including Toxoplasma (Beckers et al., 1995). This DNA 
resides in an organelle called the apicoplast. This plastid-like organelle is found in 
nearly all members of the phylum except for Cryptosporidium spp. (Zhu et al., 2000). 
The apicoplast is believed to have its origins in a secondary endosymbiotic event. 
This organelle has been investigated extensively since its discovery. It was found that 
in Toxoplasma gondii, the inhibition of apicoplast DNA synthesis blocked the 
replication of parasite. This suggests that apicoplast plays an essential role in the 
survival of the parasites (Fichera & Roos, 1997). Apart from that, the chloroplast-
derived organelles were not found in humans as well as other mammals, thus 
suggesting that the apicoplast might be useful in the study of parasite-specific targets 
in the drug development against Apicomplexa. Toxoplasma gondii has been an 
important model in the studies of apicomplast development and function.  
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Figure 1.1 The morphology of apicomplexan parasites. There are a collection of 
organelles found specifically in this phylum. The apicoplast is located next to the 
Golgi body. (Figure is adapted from Morrissette & Sibley, 2002).  
 
In the phylum Apicomplexa, Toxoplasma gondii appears to be used the most as 
experimental models for the study of apicomplexan biology (Roos et al., 1999). The 
intracellular morphology of Toxoplasma gondii is distinct (Figure 1). Besides, the 
organelles can be visualised readily using light microscope or advance electron 
microscope, despite the small size of tachyzoites, 2 × 7 µm2 (Swedlow et al., 2002). 
Furthermore, there are various experimental advantages such as the pathogenic 
stages of Toxoplasma gondii are easily propagated and quantified in the laboratory; 
the mouse animal model is well-established; and the availability of the reagents used 
in the study of the parasites, have played a major part in making the parasites being 
studied widely. 
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1.1.2 Life cycle and transmission of Toxoplasma gondii 
Toxoplasma gondii has a complex life cycle. Figure 2 illustrated the life cycle and 
transmission route of Toxoplasma gondii. This parasite has a heteroxenous life cycle 
and it can infect a wide range of warm-blooded host which includes human. An 
example of a definitive host is the domestic cats. The infectious stages of the parasite 
can be divided into three stages, namely the tachyzoites, bradyzoites and sporozoites. 
Tachyzoites and bradyzoites are contained in tissue cysts while sporozoites are in 
sporulated oocysts. All these three stages are infectious. (Hill & Dubey, 2002) 
 
The sexual cycle occurs only in the intestine of cats. Replication occurs which leads 
to the production of oocysts. This will then result in the shedding of oocysts in the 
faeces of cats for 7-21 days. Cats are able to shed millions of oocysts even if only 
one bradyzoite is ingested. Three infectious stages of Toxoplasma gondii ingested 
will lead to shedding of oocysts in cats (Dubey et al., 1970). Sporulation will take 
place and these infectious oocysts containing sporozoites will lead to tachyzoite stage 
upon ingestion by mammals including human. Infection of the parasites on human 
might also occur through the oral ingestion of tissue cysts found in raw or 
undercooked meat. 
 
Tachyzoites are oval or crescent in shape and are about 2-4 µm wide and 4-8 µm 
long (Montoya & Liesenfeld, 2004). Parasites in this stage multiply rapidly and enter 
the nucleated cells by active penetration to form cytoplasmic vacuole (Dobrowolski 
& Sibley, 1996). Repeated replication of the tachyzoites will cause the disruption of 
host cells. The tachyzoites will then enter and infect the central nervous system, the 
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eye, placental and skeletal tissues through the bloodstream. Replication of the 
parasites will cause cell death and neighbouring cells will be invaded rapidly. 
Inflammatory response and tissue destruction will be triggered in the tachyzoite stage, 
which lead to clinical manifestations of diseases. Immune response triggered will act 
as a pressure to transform tachyzoites into bradyzoites to form cysts.  
 
The difference between the structure of bradyzoites and tachyzoites is that 
bradyzoites have a nucleus situated toward the posterior end, while tachyzoites has a 
nucleus found in the central (Dubey et al., 1998). Cysts are the infective stages for 
both intermediate and definitive hosts. They are similar to tachyzoites 
morphologically but multiply slowly and express their function differently. 
Thousands of bradyzoites can be found in tissue cysts from brain cells, skeletal and 
heart muscles. After ingestion of tissue cysts by the host, proteolytic enzymes in the 
stomach and small intestine will dissolve the cyst wall. Bradyzoites released from 
cysts will then enter the small intestine and initiate the generation of the parasites 
(Dubey et al., 1998). 
 
Infection of Toxoplasma gondii in human (Figure 2) often occurs through oral route. 
Inappropriate handling of cat litters, eating undercooked meat and drinking of 
contaminated water are a few common routes of transmission of the parasites to 
human. Apart from that, infection might also occur congenitally. Congenital 
infection occurs when a woman becomes infected during her pregnancy. 
Transmission of Toxoplasma gondii might occur through blood transfusions and 
organ transplants. 
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Figure 1.2  Life cycle of Toxoplasma gondii. The figure was adapted from (Hill & 
Dubey, 2002) 
 
1.1.3 Treatment of toxoplasmosis 
Immunocompetent patients infected with toxoplasmosis are usually not treated unless 
the symptoms are severe or persistent. The combination of pyrimethamine and 
sulfadiazine has remained as the standard treatment for this disease (Petersen et al., 
2003). Pyrimethamine and sulfadiazine work by inhibiting the enzyme dihydrofolate 
reductase that is involved in the tetrahydrofolic acid synthesis (Kadri et al., 2014). 
This frequently used therapy is successful. However, many side effects like bone 
marrow suppression are observed (Bosch-Driessen et al., 2002).  
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Toxoplasma gondii infection can also be acquired by pregnant women. This may 
happen during gestation and the infection can be transmitted to the foetus (Goldstein, 
2008). Management of maternal and foetal infection varies between different 
countries. Spiramycin or combination of pyrimethamine and sulfadiazine are often 
used depending on the trimester of pregnancy (Rajapakse et al., 2013). Spiramycin is 
a macrolide antibiotic and is often used during the first 18 weeks of gestation. It was 
reported that this treatment is able to reduce the vertical transmission of  the parasite 
(Couvreur et al., 1988). However, spiramycin is not able to treat the infection in the 
foetus due to the inability of the drug to cross the placenta. Combination of 
pyrimethamine, sulfadiazine and folinic acid is used to treat pregnant women who 
are infected after 18 weeks of gestation and also for those confirmed foetal infection. 
Pyrimethamine should not be used during the first trimester of pregnancy due to the 
teratogenic potential. The drug produces dose-related depression of the bone marrow 
(Goldstein, 2008). This anti-toxoplasma treatment should be continued throughout 
the pregnancy period. Consequently, the patients who received pyrimethamine 
treatment should have their complete blood counts closely monitored.  
 
1.1.4 Role of natural products in toxoplasmosis 
Natural products continued to play a significant role in the drug discovery for the 
treatment of various human diseases. Natural products are thought to contain the 
desired properties of potency and often considered to have low toxicity. The use of 
medicinal plants for the treatment of parasitic diseases is well documented since 
ancient times. For example, Cinchona succiruba has been used to treat the infection 
of malaria for centuries (Kaur et al., 2009).  
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 Numerous natural products have been studied extensively for potential source of 
new agents to treat toxoplasmosis. Among them, Artemisia annua L., an annual herb 
belonging to the family Asteraceae, has been reported to inhibit Toxoplasma 
replication in vitro (Jones-Brando, et al. 2006; Ke et al., 1990). The active compound, 
artemisinin isolated from the plant was initially developed for anti-malaria activity 
(de Ridder et al., 2008).  
 
Medicinal herbs from South Korea were also tested for the anti-protozoal activity 
against cultures of Toxoplasma gondii. In the study, it was found that the alcohol 
extracts of Torilis japonica and Sophora flavescens demonstrated the best inhibition 
of Toxoplasma gondii among all the medicinal herbs tested (Youn et al., 2003). 
Oleuropein isolated from Fraxinus rhychophylla was investigated for its activity 
against Toxoplasma gondii both in vitro and in vivo. It was reported that oleuropein 
showed anti-toxoplasma activity in the infected mice (Jiang et al., 2008). Meanwhile 
15 methanolic extracts of Korean traditional medicine were tested on the effect on 
Toxoplasma gondii. Among them, it was reported that Zingiber officinale possesses 
high anti-toxoplasma activity as well as low cytotoxicity (Choi et al., 2008). 
 
Apart from that, maslinic acid (2α,3β-dihydroxyolean-12-en-28-oic acid) found in 
the fruits of the olive (Olea europaea) was reported to have the ability of blocking 
the entry of Toxoplasma gondii into the cells. This compound is present in many 
plants and is found mainly in the leaves and fruits of Olea europaea (De Pablos et al., 
2010). Secrurinine produced by Securinega suffructicosa was evaluated against 
Toxoplasma gondii. This widely used traditional Chinese medicine was found to 
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inhibit the growth of the parasite in vitro. This compound was also less toxic when 
compared to pyrimethamine (Holmes et al., 2011). Another compound isolated from 
the Chinese medicine was ginkgolic acid. This compound is found in Ginkgo biloba, 
a chinese herb which was reported to possess anti-microbial properties and anti-
tumor properties (Yang et al., 2004). In the study, it was reported that ginkgolic acids 
significantly inhibit Toxoplasma gondii DNA and protein synthesis at low 
concentrations (Chen et al., 2008). 
 
In Malaysia, crude methanolic extract and sub-fractions of Tinospora crispa were 
investigated on against Toxoplasma gondii. This alkaloid-rich plant was reported to 
show potential anti-toxoplasma activity (Lee et al., 2012). Eurycoma longifolia Jack 
from the Simaroubaceae family has also been tested on the activity against 
Toxoplasma gondii. It was reported that its extracts and sub-fractions significantly 
inhibit the growth of Toxoplasma gondii at low concentrations (Kavitha et al., 2012). 
 
1.1.5 Toxoplasma gondii and neurodegenerative diseases 
Toxoplasma gondii, a neurotropic parasite, when infecting immunocompromised 
hosts, often leads to severe encephalitis and neurocognitive sequelae (Daniels et al., 
2014). In year 1979, it was reported that infection of toxoplasmosis affects the 
learning performance and memory of laboratory rats and mice. It was found that, in 
the maze experiments and memory tests, infected rats and mice showed poor learning 
performance and their memory was severely affected (Witting, 1979).  
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Antipsychotic medications have been shown to have anti-protozoal activities. In vitro 
studies have evaluated the effect of antipsychotic medicines like phenothiazines, 
which was found to inhibit the growth of Leishmania donovani (Pearson et al., 1984), 
Plasmodium falciparum (Kristiansen & Jepsen, 1985) as well as Toxoplasma gondii 
(Pezzella et al., 1997).  
 
Various investigations evaluated the effects of drugs used in the treatment of 
schizophrenia on the Toxoplasma gondii. Schizophrenia is known to cause deficits in 
learning, memory as well as other cognitive functions. It still remain unclear how the 
infection contributes to cognitive deficits in schizophrenia patients. Thus, with the 
understanding of how latent infection cause deficits in learning and memory, new 
therapeutic treatments can be developed (Daniels et al., 2014).  
 
In year 2011, the possible association between toxoplasma infection and Alzheimer's 
disease was investigated. The findings suggested that toxoplasma infection may be 
involved in the pathogenesis mechanisms of Alzheimer's disease. This can serve as a 
new approach for the management of this neurodegenerative disease (Kusbeci et al., 
2011). 
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1.2 Alzheimer's disease: Overview 
Alzheimer's disease (AD) was first described more than 100 years ago. It is the most 
common cause of dementia and was first reported by a German psychiatrist named 
Alois Alzheimer in his study of a woman who suffered from progressive dementia. 
This patient had suffered from a rapid loss of memory and she had become 
disoriented in time and space. At the end of her life, she became bedridden and 
incontinent and died four and a half years later. Post-mortem examination done on 
her revealed the presence of amyloid plaques in her brain (Small & Cappai, 2006). 
AD patients will present a gradual onset, showing a decline in cognition, behavioural 
as well as motor functions. Patients suffer from AD will have their daily functioning 
and quality of life affected greatly (Geldmacher & Whitehouse, 1996). At the early 
stage of AD, symptoms of depression might be observed. Other cognitive symptoms 
include loss of short-term memory, disorientation to time, place and people, and 
language impairment.  
 
Early diagnosis of AD can be done using improved diagnosis techniques and criteria. 
Patients will can evaluated through some physical examinations, the detailed history 
of patients and their mental state will be examined by using specific cognitive and 
psychological tests (Alloul et al., 1998). However, at present, the definitive 
diagnostic can only be done by histological examination of the brain tissue.  
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1.2.1 Hypothesis of Alzheimer's disease 
Two major hypotheses have been proposed to explain the underlying molecular 
mechanism of Alzheimer's disease. One of the hypotheses is the amyloid cascade 
hypothesis. This hypothesis remains to be the best defined and most studied 
framework for Alzheimer's disease even though the exact cause of the disease is still 
being strongly debated. As described by Alois Alzheimer in his finding in year 1907, 
the detection of amyloid plaques in patients were defined as the characteristic of 
Alzheimer's disease. This hypothesis suggests that the deposition of amyloid beta 
(Aβ) will lead to neuronal dysfunction and death in the brain (Ballard et al., 2011). 
This extracellular deposits are found mostly in the neocortex and are comprised of 4-
kDa polypeptides (Glenner & Wong, 1984). Aβ is produced by the enzyme β-
secretase and subsequently by γ-secretase from a larger precursor known as the β-
amyloid protein precursor (APP) (Small & Cappai, 2006). This pathway is termed as 
amyloidogenic pathway and produces both less toxic or more toxic and highly 
aggregating Aβ depending on the cleavage sites. It was suggested that genetic and 
environmental factors might contribute to the production of more toxic Aβ, of which 
the mechanisms are not known (Tayeb et al., 2012). Accumulation of toxic Aβ leads 
to a cascade of events including an inflammatory response, free radical formation, 
oxidative stress and hyperphosphorylation of tau protein (Cummings, 2011).  
 
On the other hand, intracellular neurofibrillary tangles (NFTs), according to amyloid 
cascade hypothesis, is also another major component found in Alzheimer's disease. It 
was said that the spread of NFTs from the hippocampus and enthorhinal cortex, 
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slowly to the rest of the brain matches the clinical profile of Alzheimer's disease 
(Thal et al., 2000). NFTs are made up of hyperphosphorylated microtubule-
associated protein, tau. Tau is found widely in the brain and it belongs to the 
microtubule associated protein family. The main function of this phosphoprotein is to 
maintain the stability of microtubule (Guela et al., 1998). In Alzheimer's disease, this 
function of stabilizing the microtubules is impaired and consequently, tangles will be 
formed, leading to neurons dystrophy (Parihar & Hemnani, 2004).  
 
The second hypothesis, known as the "cholinergic hypothesis" has gained attention 
since the 1980's. Many studies supported the theory that age-related deficit in 
acetylcholine (ACh) neurotransmission leads to cognitive impairments, which is 
similar to the pathology of Alzheimer's disease. After conducting the post-mortem 
and biopsy studies, it was found that acetylcholine synthesis and activity of choline 
acetyltransferase were greatly reduced in Alzheimer's diseases patients. (Bowen et al., 
1977). In addition, the release and metabolism of acetylcholine were also reduced. 
The cholinergic deficits were caused by the extensive cell loss in neocortex, 
amygdala and hippocampus. This hypothesis was further supported by the findings 
that cholinergic neurotransmission alters memory, learning and attention where 
conditions such as senile plaques, choline acetyltransferase deficit and cognitive 
impairment were found in Alzheimer's disease patients (Geula & Mesulam, 1995). It 
was also found that when the activities of choline acetyltransferase and 
acetylcholinesterase were reduced in the cortex, the amount of senile plaques 
increased. Studies were done since the early 1980s to improve the cognitive abilities 
of animals by manipulating the cholinergic systems and inducing learning and 
memory disorders in hope to seek for potential drugs that are able to reverse this 
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alterations (Benzi & Moretti, 1998).  This was done by prolonging the availability of 
ACh released by inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase 
(BuChE) activity, which are enzymes that hydrolyze ACh in the brain.  
 
1.2.2 Role of cholinesterases in Aizheimer's Disease 
In patients of Alzheimer's disease, a decline in choline acetyltransferase and 
acetylcholinesterase (ACh) has been reported in the cerebral cortex of the brain. Both 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are involved in the 
breakdown of acetylcholine to choline and acetate and hence, terminating the 
neurotransmitter’s function in the brain. Both enzymes are found in neurons and glial 
and also neuritic plaques in Alzheimer's disease patients. Studies have suggested that 
AChE plays the role of promoting the formation of amyloid beta plaques which will 
lead to aggregation of this peptide into insoluble plaques (Rees et al., 2003). In the 
brain of Alzheimer's disease patient, BuChE activity increases whereas AChE 
activity remained unchanged or declines (Greig et al., 2002). BuChE may replace 
AChE to hydrolyze brain ACh in advanced stage of Alzheimer's disease. With the 
involvement of both AChE and BuChE in the breakdown of ACh in the brain, dual 
inhibition of these enzymes might increase the efficacy of the treatment of 
Alzheimer's disease.  
 
1.2.3 Pharmacological aspects of Alzheimer's Disease   
The major therapeutic approach to Alzheimer's disease is based on the cholinergic 
hypothesis where the main action is to affect the cognitive decline by improving the 
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cholinergic neurotransmission (Benzi & Moretti, 1998). There are many available 
strategies to enhance the cholinergic activity in the brain. However, cholinesterase 
inhibitors (ChEIs) are the best-developed therapy and are used in most mild to 
moderate stages of the disease. ChEIs work by blocking the breakdown of 
neurotransmitter acetylcholine (ACh) by acetylcholinesterase (AChE) and hence, 
prolonging the cholinergic transmission. Among many compounds developed, 
tacrine and physostigmine were evaluated most extensively on their ability to inhibit 
cholinesterase.  
 
Generally, the available cholinesterase inhibitors can be divided into three main 
classes based on the structure and mechanism. Tertiary amine compounds are the 
reversible inhibitors where this class of compounds bind to the hydrophobic region 
near the anionic α or β sites to trigger the inhibition. Drugs in this class are donepezil 
(non-competitive inhibitor) and tacrine (mixed type). Second type of the compounds 
are carbamates such as eptastigmine, which are pseudo-irreversible inhibitors and 
third type are organophosphates such as dichlorvos that are irreversible inhibitors 
(Benzi & Moretti, 1998). 
 
Tacrine was the first drug approved by the Food and Drug Administration (FDA) for 
the treatment of Alzheimer's disease in year 1993. However, adverse effects such as 
hepatotoxicity and gastrointestinal upset were reported (Camps & Achab, 2000), thus 
undermining its use as a drug. Galanthamine is a long acting, selective and reversible 
AChE inhibitor. Another drug approved by FDA for the treatment of Alzheimer's 
disease is the donepezil which is highly selective for AChE and lower affinity for 
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BuChE (Racchi et al., 2004).  Recently, it was reported that combination therapy of 
cholinesterase inhibitors with memantine has shown positive effect on the treatment 
of Alzheimer's disease of moderate to severe cases (Matsunaga et al., 2014). 
 
1.2.4 Role of natural products in Alzheimer's Disease 
Natural products play a highly significant role in the drug discovery and 
development process. In traditional practices, various plants have been used to treat 
cognitive disorders. In Indian and Chinese traditional medicine system, Bacopa 
monniera and Ginkgo biloba were used to improve cognitive disorders (Das et al., 
2002). In Korea, methanolic extracts of traditional herbs were studied for the 
improvement of memory and cognition. It was found that Acorus calamus and 
Epimedium koreanum possess cholinesterase inhibitory properties (Oh et al., 2004). 
Several plants used in the traditional medicine remedies to treat forgetfulness and to 
improve memory were studied on their AChE inhibitory activities. It was found that 
the extracts from Stephania suberosa and Tabernaemontana divaricata showed 
AChE inhibitory activity (Ingkaninan et al., 2003). In 2010, plants that are used in 
traditional European medicine to treat different central nervous system disorders or 
to improve memory were tested for their AChE as well as BuChE inhibitory effects. 
The study showed that hexane or methanolic extracts of Arnica chamissonis, Ruta 
graveolens and Hypericum perforatum showed inhibitory activity on cholinesterase 
enzymes (Wszelaki et al., 2010). 
 
Bioactive compounds were isolated from medicinal plants which contributed greatly 
to the discovery of effective drugs to treat Alzheimer's disease. Physostigmine is an 
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indole alkaloid AChE inhibitor. It was isolated from Physostigma venenosum, which 
was traditionally used as a ritual poison in Africa (Da-Yuan et al., 1996). The 
discovery of physostigmine has led to the discovery of rivastigmine. Rivastigmine is 
used in the UK for the treatment of mild to moderate Alzheimer's disease. This 
AChE inhibitor works by inhibiting AChE in the cortex and hippocampus of the 
brain (Farlow et al., 2000). Rivastigmine was tested in a group of clinically 
characterised patients with Lewy-body dementia and results showed that patients 
taking rivastigmine showed a 30% of improvement (McKeith et al., 2000). 
Galanthus nivalis was traditionally used to treat neurological conditions. An alkaloid, 
galantamine, isolated from this plant was reported to possess selective activity 
against AChE than BuChE. The drug was well-tolerated when administered to 
patients affected by Alzheimer's disease (López et al., 2002). In China, a moss which 
is used traditionally to treat dementia was tested on the cholinesterase inhibitory 
activity. The isolated huperzine A from this plant, Huperzia serrata was found to 
improve memory retention processes in studies that used aged and adult rats (Raves 
et al., 1997). 
 
Tropical forest has a large repository of the medicinal plant species. This provides an 
invaluable amount of materials for potential drug discovery. The search for 
cholinesterase inhibitors from plant source has been the main focus since the last 
decade. Natural-product based treatment on Alzheimer's disease has gained its 
popularity due to the positive outcome of previous research studies. This serves as a 
platform for future research and study to obtain effective cholinesterase inhibitors 
from plant resources. 
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1.3 Ailanthus malabarica 
The plants of the genus Ailanthus (Table 2), which belong to family of 
Simaroubaceae are distributed widely over Asia as well as north Australia. The 
Simaroubaceae family consists of 150 species of trees and shrubs. Among them, the 
genus Ailanthus plays a significant role as medicinal plant. Several species from this 
genus have been studied extensively due to their economical and medicinal 
importance. In Indian villages, majority of Ailanthus varieties have been used as 
traditional medicine. The word Ailanthus comes from ailanto. It is an Ambonese 
word that means "tree of heaven". These plants can grow up to 25-45m tall, with 
spreading branches and large pinnate leaves (Laskar, 2010). 
 
Table 1.2  Taxonomic classification of Ailanthus malabarica 
 
Taxonomic Classification 
Kingdom Plantae 
Phylum Magnoliophyta 
Class Magnoliopsida 
Order Sapindales 
Family Simaroubaceae 
Genus Ailanthus 
Species malabarica 
